Abstract
Purpose
The first-generation protease inhibitors (PI) boceprevir and telaprevir combined with pegylated interferon have revolutionized the treatment of type-1 hepatitis C by increasing the rates of sustained virologic response. However, they induce drug interactions, and their clinical relevance is difficult to predict. This review compiles available data on drug–drug interactions (DDI) based on their pharmacokinetic and pharmacodynamic properties with the aim of assisting clinicians in managing DDI
Methods
PubMed, drug interaction databases and hepatology and infectious disease conference abstracts were systematically searched using the key search terms “interaction”, “hepatitis C”, “telaprevir” and “boceprevir”. All known interactions were compiled and reclassified according to their pharmacokinetic and pharmacodynamic mechanisms. The state of knowledge of interaction mechanisms are reported and a therapeutic approach is proposed.
Results
Boceprevir and telaprevir are both substrates and potent inhibitors of cytochrome P450 3A4 and the drug transporter P-glycoprotein. They induce overdosage but can sometimes decrease the effect of other drugs by inducing other cytochromes. Overdosage or low dosage mainly affects drugs with a narrow therapeutic range, such as immunosuppressants or antiretrovirals. The distribution and elimination of PI are unaffected by interactions. In terms of pharmacodynamic interactions, PI can trigger drug-induced QT interval prolongation, which means that clinicians should manage such risk factors as potassium/magnesium levels or avoid other QT-prolonging drugs.
Conclusions
Management of hepatitis C therapy is complex. The key to interpreting DDI data is a solid understanding of the pharmacokinetic and pharmacodynamic profiles of the drugs involved. Their ability to inhibit cytochrome P450 3A4 and prolong the QT interval can have significant clinical consequences. This review provides a practical guide to the safe and effective management of therapy with boceprevir and telaprevir.
Similar content being viewed by others
References
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH et al (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362(14):1292–1303
Sherman KE, Flamm SL, Afdhal NH et al (2011) Response-guided Telaprevir combination treatment for Hepatitis C Virus infection. N Engl J Med 365(11):1014–1024
Poordad F, McCone J, Bacon BR et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195–1206
Zeuzem S, Andreone P, Pol S et al (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364(25):2417–2428
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4):1433–1444
Merck Canada Inc (2013) Victrelis (Boceprevir) product monograph. Merck Canada Inc, Kirkland
Vertex Pharmaceuticals Inc. (2013) Incivek (Telaprevir) product monograph. Vertex Pharmaceuticals Inc., Laval
Kasserra C, Hughes EA, Treitel M (2011) Clinical pharmacology of Boceprevir: metabolism, excretion, and drug-drug interactions (abstract 118). In: Abstract book of the 18th Conference on Retroviruses and Opportunistic Infections. Boston
Levêque D, Lemachatti J, Nivoix Y et al (2010) Mécanismes des interactions médicamenteuses d’origine pharmacocinétique. Rev Med Intern 31(2):170–179
Van Heeswijk R, Boogaerts G, De Paepe E. (2011) The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor Telaprevir (abstract PK_19). In: Abstract book of the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases (6):21. Cambridge
Benet L, Hoener B (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121
Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42(1):59–98
Ghosal A, Yuan Y, Tong W, Su A-D et al (2011) Characterization of human liver enzymes involved in the biotransformation of Boceprevir, a Hepatitis C Virus protease inhibitor. Drug Metab Dispos 39(3):510–521
Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RPG (2012) Effect of Telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 52(10):1566–1573
Jumes P, Feng H-P, Xuan F, et al (2012) Pharmacokinetic interaction between the HCV protease inhibitor Boceprevir and Digoxin in healthy adult volunteers (abstract PK_05). In: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases (7):8 Cambridge
Burger D, Back D, Buggisch P et al (2013) Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions. J Hepatol 58(4):792–80020
Kis O, Robillard K, Chan G, Bendayan R (2010) The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22–25
Henshaw J, Adiwijaya B, Adda N, et al (2012) The pharmacokinetics of Telaprevir and selected ART medications in HCV/HIV co-infected patients (abstract PK_08). In: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy Reviews in Antiviral Therapy & Infectious Diseases (7):11. Cambridge
Van Heeswijk R, Vandevoorde A, Boogaerts G, et al (2011) Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers (abstract 119]. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston
Neuvonen P, Niemi M, Backman J (2006) Drug interactions with lipid lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581
Hulskotte EG1, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR (2013) Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor Boceprevir and the HMG-CoA reductase inhibitors Atorvastatin and Pravastatin. Antimicrob Agents Chemother 57(6):2582–8
Kunze A, Huwyler J, Camenisch G et al (2012) Interaction of the antiviral drug Telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 84:1096–1102
Huang S-M, Temple R, Throckmorton DC, Lesko LJ (2007) Druginteraction studies: Study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81(2):298–304
Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X (2011) Effect of Telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54(1):20–27
Hulskotte E1, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J (2012) Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 56(5):1622–30
Kiser JJ, Burton JR, Anderson PL, Everson GT (2012) Review and management of drug interactions with Boceprevir and Telaprevir. Hepatology 55(5):162–168
Wilby KJ, Greanya ER, Ford JAE, Yoshida E, Partovi N (2012) A review of drug interactions with Boceprevir and Telaprevir: implications for HIV and Transplant patients. Ann Hepatol 11(2):179–185
Saxena V, Terrault N (2012) Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 17(3):216–224
Coilly A, Furlan V, Roche B, Barau C et al (2012) Practical management of Boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 56(11):5728–5734
O’Leary JG, McKenna GJ, Klintmalm GB, Davis GL (2013) Effect of Telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl 19(4):463–465
Vourvahis M, Plotka A, Kantaridis C, et al (2013) The effect of Boceprevir and Telaprevir on the pharmacokinetics of Maraviroc: an open-label, fixed-sequence study in healthy volunteers [O_17]. In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases (3):20 Amsterdam
Van Heeswijk RP, Beumont M, Kauffman RS, Garg V (2013) Review of drug interactions with Telaprevir and antiretrovirals. Antivir Ther 18(4):553–560
De Kanter CTMM, Blonk MI, Colbers APH, Schouwenberg BJJW, Burger DM (2013) Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor Boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 56(2):300–306
Henshaw J, Adiwijaya B, Adda N, et al. (2012) The pharmacokinetics of Telaprevir and selected ART medications in HCV/HIV co-infected patients [abstract PK_08]. In: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases (7):11 Cambridge
Moreno A, Quereda C, Montes M et al (2012) Safe coadministration of raltegravir-based HAART in HIV infected patients with HCV-cirrhosis receiving triple therapy with Telaprevir or Boceprevir. J Acq Immune Def Syndr 61(3):e47–e49
Van Heeswijk RPG, Garg V, Boogaerts G, et al (2011) The pharmacokinetic interaction between Telaprevir and raltegravir in healthy volunteers (abstract A1-1738a). In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago
Seden K, Back D (2011) Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 6(6):514–526
Piroth L (2011) Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. Clin Res Hepatol Gastroenterol 35[Suppl 2]:S75–S83
Garg V, Chandorkar G, Yang Y, Adda N et al (2013) The effect of CYP3A inhibitors and inducers on the pharmacokinetics of Telaprevir in healthy volunteers. Br J Clin Pharmacol 75(2):431–439
Rangnekar AS, Fontana RJ (2012) Managing drug-drug interactions with Boceprevir and Telaprevir. Clin Liv Dis 1(2):36–40
Van Heeswijk RPG, Vandevoorde A, Boogaerts G et al (2011) Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers (abstract 119). In: 18th Conference on Retroviruses and Opportunistic Infections. Boston
Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brøsen K (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60(2):109–114
Zheng HX, Huang Y, Frassetto LA, Benet LZ (2009) Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85(1):78–85
Van Giersbergen PLM, Treiber A, Schneiter R, Dietrich H, Dingemanse J (2007) Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81(3):414–419
Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N (2012) The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor Telaprevir. J Clin Pharmacol 52(10):157–1583
Gatti DC, Cha A (2012) Apparent interaction between Telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health Syst Pharm 69(23):2062–2065
Roden D (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350:1013–1022
University of Arizona Center for Education and Research on Therapeutics. Available at: www.qtdrugs.org
Nolan M (2012) EMA approved new drugs: Telaprevir and Boceprevir Direct acting antivirals rewrite guidelines for the treatment of hepatitis. Eur J Hosp Pharm 19:299–300
Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM (2003) What clinicians should know about the qt interval—correction. JAMA 290(10):1318
Hulskotte EGJ, Gupta S., Xuan F. et al (2011) Coadministration of the HCV protease inhibitor Boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. (Abstract 121) published in Global Antiviral Journal, Volume 7, Suppl. 1: HEP DART 2011: 121 Koloa, Hawaii
Hulskotte EGJ, Feng H-P, Xuan F et al (2013) Pharmacokinetic evaluation of the interaction betweenthe HCV protease inhibitor Boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother 57:2582–2588
Hulskotte EGJ, Gupta G, Xuan F, et al (2012) Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. (Abstract 121) published in Global Antiviral Journal, Volume 7, Suppl. 1: HEP DART 2011: 110
Hulskotte EGJ, Feng H-P, Xuan F, et al (2013) Pharmacokinetic interactions between the HCV protease inhibitor Boceprevir and sirolimus in healthy subjects (abstract 463). In: 48th Annual Meeting of the European Association for the Study of the Liver (EASL. J. Hepatology 2013 (58), Supplement 1 : S1-S632)
Garraffo R, Lavrut T, Poisot-Martin I, et al (2013) Pharmacokinetic interactions between Boceprevir and atazanavir/ritonavir or raltegravir in HIV/HCV coinfected patients (abstract O_15). In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases (3):18. Amsterdam
Hammond K, Wolfe P, Burton J et al (2013) Pharmacokinetic interaction between Boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acq Immune Def Syndr 62(1):67–73
Hulskotte EG1, Feng HP, Xuan F, et al (2013) Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 56(5):718–26
Rhee E, Feng H-P, Xuan F et al (2013) Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor Boceprevir and HIV-1 NNRTI rilpivirine (abstract 537). In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta
Vourvahis M, Plotka A, Kantaridis C et al. (2013) The effect of Boceprevir and Telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers (O_17). In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Published in Reviews in Antiviral Therapy & Infectious Diseases (3):20. Amsterdam
Johnson M, Borland J, Chen S et al (2013) The effect of Boceprevir and Telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects [abstract O_16]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, published in Reviews in Antiviral Therapy & Infectious Diseases (3):19. Amsterdam
Lin WH, Feng H-P, Chatterjee M et al (2012) Pharmacokinetic interaction between the hepatitis C virus protease inhibitor Boceprevir and ethinylestradiol/norethindrone (abstract 1901). In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 56(4):1078A. Boston
Jumes P, Feng H-P, Chatterjee M et al (2012) Pharmacokinetic interaction between the hepatitis Cvirus protease inhibitor Boceprevir and prednisone in healthy volunteers (abstract 1896). In: 63rdAnnual Meeting of the American Association for the Study of Liver Diseases. Hepatology 56(4):1076A. Boston
de Kanter CT1, Colbers AP, Blonk MI, Verweij-van Wissen CP, Schouwenberg BJ, Drenth JP, Burger DM. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. J Antimicrob Chemother. 2013 Jun;68(6):1415–22
Hulskotte EGJ, Feng H-P, Bruce RD et al (2012) Pharmacokinetic interaction between HCV protease inhibitor Boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy (abstract PK_09). 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases 2012 (7):12. Cambridge
Poordad F, Lawitz E, Gordon S, et al (2011) Concomitant medication use in patients with hepatitis C genotype 1 treated with Boceprevir combination therapy ([poster 937). In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco Hepatology 54(4):799A. San Francisco
van Heeswijk R, Boogaerts G, De Paepe E, van Solingen-Ristea R, Garg V, Beumont M. (2010) The pharmacokinetic (PK) interaction between escitalopram and the investigational HCV protease inhibitor Telaprevir. Presented at the 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Threapy and Infectious disease 5:12
Luo X, van Heeswijk R, Alves K, Garg V (2011) The effect of Telaprevir on the pharmacokinetics of Alprazolam and Zolpidem in healthy volunteers (abstract PK_11). In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Threapy and Infectious Diseases 6:13. Cambridge
Lee JE, Van Heeswijk RPG, Alves K et al (2011) Effect of the hepatitis C virus protease inhibitor Telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 55(10):4569–4574
Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP (2012) Effect of Telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 52(10):1566–1573
Van Heeswijk RPG, Verboven P, Vandevoorde A et al (2013) Pharmacokinetic interaction between Telaprevir and methadone. Antimicrob Agents Chemother 57:2304–2309
Van Heeswijk R, Vandevoorde A, Verboven P et al (2011) The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor Telaprevir. J Hepatol 54:S491–S49.2
Luo X, Trevejo J, Van Heeswijk RPG et al (2012) Effect of Telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother 56(7):3641–3647
Kraft K, Martin D, Streepey D et al (2012) Telaprevir interferes with levothyroxine treatment of hypothyroidism (abstract 1845). In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Hepatology 56(4):1053A. Boston
Gatti DC, Cha A (2012) Apparent interaction between Telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health Syst Pharm 69(23):2062–2065
Hammond KP, Jimmerson L, MacBrayne CE et al (2013) Increased plasma and intracellular ribavirin concentrations associated with Telaprevir use. (Abstract PP_2) In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 3:26. Amsterdam
Garg V, Luo X, McNair L et al (2011) Low-dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor Telaprevir in healthy volunteers (abstract 629). In: 18th Conference on Retroviruses and Opportunistic Infections. Boston
Van Heeswijk R, Gysen V, Googaerts G, et al (2008) The pharmacokinetic interaction between tenofovirdisoproxilfumarate and the investigational HCV protease inhibitor Telaprevir (abstract A-966). In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DC
Custodio JM, Guo S, Lawson E et al. (2013) Lack of clinically relevant drug interactions between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxilfumarate and Telaprevir. (Abstract A-1576) In 53th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver
Vourvahis M, Plotka A, Kantaridis C et al (2013) The effect of Boceprevir and Telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers (O_17). In: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 3:20. Amsterdam
Hulskotte EGJ,Gupta G, Xuan F, et al. (2013) Lack of Clinically Relevant Drug Interactions Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Telaprevir (Abstract 1576) 53th International Congress on Antimicrobial Agents and Chemotherapy, Denver. Accessed 10-13 Sept 2013
Johnson M, Borland J, Chen S et al (2013) The effect of Boceprevir and Telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects (abstract O_16). In: 14th International Workshop onClinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 3:19. Amsterdam
Kakuda TN, Leopold L, Nijs S et al (2012) Pharmacokinetic interaction between etravirine or rilpivirine and Telaprevir: a randomised, two-way crossover trial (abstract O_18). In: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Reviews in Antiviral Therapy & Infectious Diseases 2013. 3:21. Barcelona
Garg V, Kauffman RS, Beaumont M, van Heeswijk RPG (2012) Telaprevir: pharmacokinetics and drug interactions. Antivir Ther (Lond) 17(7):1211–1221
Adiwijaya B, Chandorkar G, Van Heeswijk RPG et al (2011) Effect of mild and moderate hepatic impairment on Telaprevir pharmacokinetics (abstract PK_1). In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Reviews in Antiviral Therapy & Infectious Diseases 2011. 6:3. Cambridge
Acknowledgments
The authors would like to thank Marion Goutte for her contribution in improving the English of the manuscript.
Financial support/Conflict of interest
This research did not receive any financial support. The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Talavera Pons, S., Lamblin, G., Boyer, A. et al. Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?. Eur J Clin Pharmacol 70, 775–789 (2014). https://doi.org/10.1007/s00228-014-1679-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-014-1679-9